Mecain (Mepivacaine Hydrochloride)

Mepivacaine hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing sodium influx that is essential for depolarization. By inhibiting nerve impulse generation and propagation, it produces a rapid, reversible loss of sensation without affecting surrounding tissues.

The appropriate dose of Mecain is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Dosage must follow the prescriber’s instructions and local regulatory guidelines.

Safety data for mepivacaine hydrochloride in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To request Mecain, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mecain (mepivacaine) is an amide‑type local anesthetic with a rapid onset and intermediate duration, similar to lidocaine but with slightly longer analgesia. Compared with bupivacaine, it has a lower risk of cardiotoxicity and a shorter duration, making it suitable for procedures requiring moderate anesthesia time.

Mecain should be stored below 25 °C in its original packaging, protected from light and moisture. The container must remain sealed until use, and any unused solution should be discarded according to local regulations after the labeled expiration date.

Mecain is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via epidural, infiltration, intradermal or subcutaneous injection, depending on the clinical indication and desired area of anesthesia.

Serious risks include allergic reactions such as anaphylaxis, cardiac arrhythmias or severe hypotension, and central nervous system toxicity leading to seizures. Immediate medical attention is required if any of these events occur during or after administration.

Mecain should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals in whom the risk of systemic toxicity outweighs the benefit of local anesthesia. Clinical judgment is essential for each patient.